Management of Chronic Stable Angina

Medications for Event Prevention

The European Society of Cardiology recommends a dual-strategy approach, including medications for symptom relief and event prevention, such as antiplatelet agents, statins, and ACE inhibitors, for all patients with chronic stable angina 1, 2
Aspirin 75-100 mg once daily is mandatory for all patients with chronic stable angina, particularly those with prior MI or revascularization, as recommended by the European Heart Journal 1, 2, 3
Statins are mandatory in all patients with chronic stable angina, regardless of baseline cholesterol levels, due to proven mortality reduction, as stated by the European Heart Journal and Annals of Internal Medicine 1, 4
ACE inhibitors are recommended for patients with hypertension, diabetes, heart failure, LV dysfunction, or prior MI, as suggested by the Annals of Internal Medicine 4

The European Heart Journal recommends sublingual nitroglycerin for immediate relief of angina episodes and situational prophylaxis 1, 2
Beta-blockers are the preferred initial antianginal agent due to mortality benefits in post-MI patients and proven symptom control, as recommended by the European Heart Journal 1, 2

The European Heart Journal suggests exercise-based cardiac rehabilitation, which significantly reduces cardiovascular mortality while improving risk factor control 1, 6
Aerobic physical activity, such as 150-300 minutes per week of moderate intensity, is recommended for patients with chronic stable angina, as stated by the European Heart Journal 2

The European Heart Journal recommends reviewing patient response to medical therapies at 2-4 weeks after drug initiation and clinical follow-up every 4-12 months 1, 6
The American College of Cardiology suggests patient education about the disease, risk factors, and treatment strategy is essential for long-term adherence 7